Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the clinical equivalence of the test formulation
of mometasone furoate anhydrous 50 mcg/actuation nasal spray (manufactured by Teva
Pharmaceutical Industries, Ltd. and distributed by Teva Pharmaceuticals USA) to the marketed
formulation Nasonex® (mometasone furoate monohydrate) nasal spray, 50 mcg/actuation
(Schering) in patients with seasonal allergic rhinitis.
In addition, the efficacy of both the test and reference nasal sprays will be compared to a
placebo nasal spray and safety will be compared.